[
  {
    "question": "Brain MRI showing mass originating from fourth ventricle Histology showing pseudorosette ependymoma",
    "option_a": "",
    "option_b": "is correct",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuro-oncology",
    "explanation": "Ependymomas are glial tumors that arise from ependymal cells lining the ventricular system. They often occur in the posterior fossa in children and in the fourth ventricle in adults, with specific histological features. Ependymomas develop from the ependymal cells that line the ventricles and central canal. The key microscopic feature is the formation of perivascular pseudorosettes, where tumor cells are oriented around blood vessels, separated by an intervening zone of fibrillary processes. Patients with a fourth ventricular ependymoma may present with symptoms of increased intracranial pressure, cerebellar signs, and hydrocephalus. The MRI hallmark is a mass originating within or adjacent to the fourth ventricle, which may cause obstructive hydrocephalus. Differential diagnoses for a fourth ventricle mass include medulloblastoma (which typically occurs in the cerebellar vermis with Homer Wright rosettes), pilocytic astrocytoma (characterized by cystic lesions with mural nodules and Rosenthal fibers), and choroid plexus tumors (exhibiting papillary structures). Histological identification of perivascular pseudorosettes firmly supports the diagnosis of ependymoma. The mainstay of treatment for ependymomas is maximal safe surgical resection, often followed by adjuvant radiotherapy, especially in cases of incomplete resection or higher grade tumors. In pregnant or lactating patients, surgical timing and radiotherapy require careful planning to mitigate fetal or neonatal risks; alternative strategies or deferrals may be considered in certain cases. Option B is correct \u2013 perivascular pseudorosettes are pathognomonic for ependymoma. Other options such as medulloblastoma, pilocytic astrocytoma, or choroid plexus tumors have distinct histological features that do not include pseudorosettes, making them incorrect in this context. 1. Fourth ventricular tumors in children and adults should raise suspicion for ependymoma, particularly when imaging demonstrates an intraventricular origin. 2. Histopathological identification of perivascular pseudorosettes confirms the diagnosis. 3. Surgical resection is the key step in management, with adjuvant therapy reserved for high-grade or residual tumors. Current research emphasizes the importance of complete surgical resection in determining long-term outcomes. Advances in molecular profiling are also improving prognostication and guiding adjuvant therapy protocols in ependymoma, in line with updated WHO classification guidelines.",
    "exam_year": "2020",
    "exam_type": "Part I",
    "image_url": "page_31.png"
  },
  {
    "question": "Boy with Headache more in the morning associated with N/V what to do next",
    "option_a": "(CT brain) is correct because it promptly identifies life\u2010threatening causes of raised ICP. Lumbar puncture is contraindicated before imaging due to the risk of brain herniation. MRI, although sensitive, requires longer acquisition times and isn\u2019t as readily available in emergencies. Symptomatic treatment would delay vital diagnostic steps.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Neuro-oncology",
    "explanation": "A child presenting with morning headache and nausea/vomiting raises concern for increased intracranial pressure (ICP), a critical red flag that warrants prompt evaluation. The core concept is that such symptoms can be an early sign of an intracranial mass, hydrocephalus, or another process that elevates ICP. During sleep, especially in the supine position, intracranial pressure may rise due to decreased venous drainage. When ICP is elevated as a result of a space-occupying lesion or obstructive hydrocephalus, this pressure can stimulate brainstem structures leading to nausea and vomiting. In children, even benign lesions can have significant effects because of the pliability of their cranial vaults and developing brains. Morning headaches that improve over the course of the day and are accompanied by nausea/vomiting are highly concerning. These symptoms suggest that the intracranial pressure is highest upon waking, pointing toward a mass effect or hydrocephalus. This clinical pattern demands immediate imaging to assess for underlying pathology. The initial evaluation focuses on neuroimaging. CT brain without contrast is the first-line test because it is fast, widely available, and effective at identifying masses, hemorrhage, hydrocephalus, or midline shifts. Differential diagnoses such as migraine or tension headache are less likely in the presence of these red flag symptoms, and imaging helps to quickly rule out life\u2010threatening causes. According to current guidelines, the first-line management for a child with signs of raised ICP is urgent neuroimaging \u2013 CT brain is typically recommended. If findings are positive, a neurosurgical consult is indicated for further management. In emergency situations, even in pregnancy (with appropriate abdominal shielding), CT imaging may be performed if clinically warranted, although in children the risk of ionizing radiation is always carefully considered. Option A (CT brain) is correct because it promptly identifies life\u2010threatening causes of raised ICP. Lumbar puncture is contraindicated before imaging due to the risk of brain herniation. MRI, although sensitive, requires longer acquisition times and isn\u2019t as readily available in emergencies. Symptomatic treatment would delay vital diagnostic steps. 1. Morning headache with nausea/vomiting in a child is a red flag for increased ICP. 2. A CT scan is the rapid imaging modality of choice to detect intracranial pathology. 3. Lumbar puncture must be avoided until intracranial masses are ruled out due to the risk of herniation. Recent guidelines and studies consistently emphasize the urgent use of CT imaging in pediatric patients with signs of raised ICP. This approach remains the standard of care to quickly identify intracranial hemorrhage, tumors, or hydrocephalus and to triage the need for urgent neurosurgical intervention.",
    "exam_year": "2020",
    "exam_type": "Part I"
  },
  {
    "question": "Case scenario of a patient with findings suggestive of NF1, asked about what it comes with?",
    "option_a": "Bilateral Vestibular Tumor",
    "option_b": "Bilateral Optic Glioma",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuro-oncology",
    "explanation": "Neurofibromatosis type 1 (NF1) is an autosomal dominant neurocutaneous disorder characterized by multiple caf\u00e9-au-lait spots, neurofibromas, and other systemic findings. One of the hallmark associations in NF1 is with optic pathway glioma. NF1 results from a mutation in the NF1 gene located on chromosome 17, leading to a deficiency in neurofibromin, a tumor suppressor protein. This loss predisposes patients to the development of various benign and malignant neoplasms, including optic pathway gliomas, which can compromise visual pathways. Patients with NF1 often present in childhood with skin findings like caf\u00e9-au-lait spots and freckling in the axilla, accompanied by the development of neurofibromas. Optic pathway gliomas, though not always bilateral, are a well-recognized potential complication that can affect vision and require periodic screening. Diagnosis of NF1 is primarily clinical and based on established criteria (e.g., NIH criteria). Ophthalmologic evaluation, including slit-lamp examination for Lisch nodules, as well as neuroimaging for optic pathway evaluation in patients with visual symptoms, is recommended. Differential considerations include NF2, which is primarily associated with bilateral vestibular schwannomas. Management of NF1 is mainly supportive and involves regular surveillance. For optic gliomas, if they are asymptomatic the approach is often conservative with periodic observation. If there is progression or visual compromise, chemotherapy (e.g., vincristine and carboplatin) may be considered. During pregnancy and lactation, management requires careful monitoring due to the potential for hormonal changes to affect tumor growth, and genetic counselling is recommended. Option A (Bilateral Vestibular Tumor) corresponds to NF2 rather than NF1. Option B (Bilateral Optic Glioma) aligns with the association in NF1, though it is more typically described as optic pathway glioma; this remains the best answer in the context of NF1. Other choices (if provided) would be less specific to NF1. 1. NF1 is strongly associated with caf\u00e9-au-lait spots, neurofibromas, and optic pathway gliomas. 2. NF2 should be considered when bilateral vestibular schwannomas are present. 3. Regular ophthalmologic screening is critical in children with NF1. Contemporary studies continue to support regular screening for optic pathway gliomas in children with NF1. Updated guidelines stress multidisciplinary care including neurology, ophthalmology, and genetics to optimize long-term outcomes.",
    "exam_year": "2021",
    "exam_type": "Part I"
  },
  {
    "question": "Patient with retinal lesions and cerebellar hemangioblastoma in his brother what is the diagnosis?",
    "option_a": "Von Hipple Lindau",
    "option_b": "Sturge Weber Syndrome",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuro-oncology",
    "explanation": "Von Hippel-Lindau (VHL) disease is an inherited multisystem condition characterized by the development of highly vascular tumors. The presence of retinal lesions along with a family history of cerebellar hemangioblastoma is classic for VHL. VHL disease arises from a mutation in the VHL tumor suppressor gene, leading to abnormal regulation of hypoxia-inducible factors (HIFs). This aberrant pathway encourages angiogenesis, resulting in the development of hemangioblastomas in the retina, cerebellum, and other sites, as well as a predisposition to renal cell carcinoma and pheochromocytoma. Patients with VHL often present with retinal hemangioblastomas and central nervous system lesions such as cerebellar hemangioblastomas. The combination of these findings in a patient with a suggestive family history is highly indicative of VHL disease. In contrast, conditions like Sturge-Weber syndrome are associated with port-wine stains and leptomeningeal angiomas rather than hemangioblastomas. The diagnosis is based on a combination of clinical findings, family history, and confirmatory genetic testing. Differential diagnoses include Sturge-Weber syndrome, which typically presents with skin and leptomeningeal vascular malformations, but not with retinal or cerebellar hemangioblastomas. Management involves regular surveillance with MRI of the brain and spine, ophthalmologic examinations, and periodic abdominal imaging for renal tumors. Interventions may include surgical resection or radiotherapy as necessary. In pregnancy and lactation, management must balance intervention risks with fetal exposure; a multidisciplinary approach is essential, often postponing elective surgeries until after delivery if possible. Option A (Von Hippel Lindau) is correct because the combination of retinal lesions and cerebellar hemangioblastomas is pathognomonic for VHL. Option B (Sturge Weber Syndrome) is incorrect since it is characterized by facial port-wine stains and leptomeningeal angiomas rather than hemangioblastomas. 1. VHL disease is marked by the presence of retinal and cerebellar hemangioblastomas. 2. A detailed family history is crucial for diagnosing inherited syndromes such as VHL. 3. Sturge-Weber syndrome, although a neurocutaneous disorder, follows a completely different clinical pattern. Recent guideline updates emphasize early genetic screening and regular imaging surveillance in VHL to detect lesions early and reduce morbidity. Research continues to investigate targeted therapies that modulate the HIF pathway in VHL-related tumors.",
    "exam_year": "2021",
    "exam_type": "Part I"
  },
  {
    "question": "Case scenario of a patient with hypopituitarism, pituitary mass and meningeal enhancement. I forgot the details, next?",
    "option_a": "MRA",
    "option_b": "MRV",
    "option_c": "MRI orbit",
    "option_d": "CT chest",
    "option_e": "",
    "correct_answer": "D",
    "subspecialty": "Neuro-oncology",
    "explanation": "A patient presenting with hypopituitarism, a pituitary mass, and meningeal enhancement suggests an infiltrative or inflammatory process affecting the sellar region. The clinical picture raises suspicion for a systemic granulomatous disease, such as neurosarcoidosis, which can involve the hypothalamic-pituitary axis. Neurosarcoidosis is characterized by non-caseating granulomas that can infiltrate the meninges and the pituitary gland, leading to both anterior and posterior pituitary dysfunction. This inflammatory process results in imaging findings such as pituitary enlargement and meningeal enhancement. The systemic nature of sarcoidosis often includes pulmonary involvement. Patients with neurosarcoidosis may present with various endocrine abnormalities including hypopituitarism and diabetes insipidus. The MRI findings of a pituitary mass with associated meningeal enhancement are clues that prompt evaluation for systemic sarcoidosis, particularly when central nervous system involvement is evident. The differential diagnosis includes pituitary adenomas, lymphocytic hypophysitis, germ cell tumors, and infectious conditions like tuberculosis. A CT chest is a pivotal next step, as it can reveal bilateral hilar lymphadenopathy \u2013 a hallmark of sarcoidosis. Laboratory evaluations (e.g., serum ACE levels) and possibly a biopsy may also be warranted. First-line treatment for neurosarcoidosis typically involves high-dose corticosteroids. If patients do not respond adequately, second-line immunosuppressive agents such as methotrexate or azathioprine may be considered. For the diagnostic workup, performing a CT chest is essential to evaluate for pulmonary involvement. In pregnant or lactating patients, low-dose corticosteroids may be used judiciously with careful monitoring, and imaging protocols should minimize radiation exposure (with proper shielding if CT is necessary). Option A (MRA) is used for vascular evaluation and is not indicated here. Option B (MRV) targets venous sinus thrombosis, which does not match the clinical picture. Option C (MRI orbit) is irrelevant in this context. Option D (CT chest) is correct because it helps to detect pulmonary manifestations (such as hilar lymphadenopathy) that support a diagnosis of sarcoidosis. 1. In neurosarcoidosis, consider a CT chest to assess for bilateral hilar adenopathy. 2. Meningeal enhancement in the context of a sellar mass strongly suggests an inflammatory or infiltrative systemic process. 3. Early detection and management of neurosarcoidosis are crucial to prevent permanent endocrine deficits. Recent research supports the use of CT chest as a non-invasive diagnostic aid in suspected neurosarcoidosis. Updated guidelines continue to favor corticosteroids as first-line therapy, with careful risk\u2013benefit analysis in pregnant and lactating patients to minimize fetal exposure while managing maternal disease.",
    "exam_year": "2021",
    "exam_type": "Part I"
  },
  {
    "question": "Case scenario of a patient with active but not yet treated renal cell carcinoma, came with headache, brain imaging reported single mass with surrounding edema, treatment?",
    "option_a": "Surgical removal!!!!!",
    "option_b": "Intrathecal chemo",
    "option_c": "Total brain radiation",
    "option_d": "Biological treatments",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuro-oncology",
    "explanation": "Brain metastases occur when cancer cells spread from a primary tumor (here, renal cell carcinoma) to the brain. When the metastasis is solitary and accessible, surgical removal is often the treatment of choice as it may provide rapid symptom relief and improve overall outcomes. Renal cell carcinoma can metastasize hematogenously. Once cancer cells lodge in the brain, they proliferate, leading to a mass lesion. The tumor\u2019s growth causes vasogenic edema in the surrounding brain tissue, resulting in increased intracranial pressure and symptoms such as headache. Patients may present with focal neurological deficits or general symptoms (eg, headache) due to mass effect. In a patient with known active RCC and a single brain mass with edema on imaging, the clinical picture is typical for an isolated brain metastasis. Diagnosis is based on neuroimaging \u2013 typically MRI with contrast to delineate the lesion and edema. Differential diagnoses include primary brain tumors (eg, glioblastoma) and abscesses, but a known history of RCC strongly suggests a metastatic lesion. Latest guidelines recommend that for a single, accessible brain metastasis, surgical resection is the first-line treatment to alleviate mass effect and provide tissue diagnosis. This is often followed by local adjuvant therapy (stereotactic radiosurgery or limited-field radiotherapy) to reduce the risk of local recurrence. In the case of pregnant or lactating patients, the risks of radiotherapy and anesthesia are carefully weighed against the benefits, with surgical planning involving multidisciplinary teams to minimize fetal exposure and optimize maternal outcomes. Option A (Surgical removal) is correct because solitary metastases in accessible locations are best managed surgically. Option B (Intrathecal chemo) is not indicated for parenchymal brain metastases. Option C (Total brain radiation) is typically reserved for multiple metastases or as adjuvant therapy and is not first-line for solitary lesions. Option D (Biological treatments) is not considered standard primary management for brain metastases. 1. A solitary brain metastasis in a patient with systemic cancer is best approached with surgical resection when feasible. 2. Managing peritumoral edema with corticosteroids is an important adjunct to reduce intracranial pressure pre- and post-operatively. Recent NCCN and EANO guidelines emphasize a combined approach for solitary brain metastases, with surgical resection followed by focused radiotherapy yielding improved local control and survival outcomes compared to radiation alone.",
    "exam_year": "2021",
    "exam_type": "Part I"
  },
  {
    "question": "Male i think his (Age was above 50) with subcortical/cortical Mets, What is the most likely primary origin of his brain Mets?",
    "option_a": "Prostate ca",
    "option_b": "lung ca",
    "option_c": "breast ca (he was male)",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuro-oncology",
    "explanation": "Brain metastases most commonly arise from cancers like lung, breast, melanoma, and renal cell carcinoma. In men, lung cancer is the most frequent primary source of brain metastases. Tumor cells from lung carcinomas enter the arterial circulation and can bypass the lung\u2019s filtering mechanisms, thereby seeding the brain. They tend to lodge in the cortical and subcortical regions due to vascular distribution. In males over 50 with brain metastases, particularly affecting the cortical/subcortical regions, lung cancer is the primary suspect. Symptoms may include headaches, cognitive changes, or motor deficits depending on lesion location. Workup includes thorough imaging studies such as chest CT and brain MRI with contrast. Differential diagnoses include metastases from melanoma, renal cell carcinoma, or even primary central nervous system tumors; however, the patient\u2019s demographics and lesion distribution help narrow the diagnosis. Management of brain metastases from lung cancer involves a multidisciplinary regimen which may include surgical resection or stereotactic radiosurgery for solitary lesions, and whole-brain radiotherapy for multiple lesions. Systemic therapy targeting the lung primary (such as targeted agents or immunotherapy) may be incorporated. In pregnant or lactating patients, treatment modifications (e.g., timing of radiotherapy or use of systemic agents) are carefully considered to minimize fetal exposure. Option A (Prostate cancer) is unlikely as prostate cancer rarely metastasizes to the brain. Option B (Lung cancer) is correct due to its high incidence as the primary source of brain metastases in older males. Option C (Breast cancer) is more common in females and is less likely in a male patient. Option D is not provided. 1. Lung cancer is the leading cause of brain metastases in males over 50. 2. Always consider a systematic evaluation for a primary lung lesion in patients presenting with brain metastases of unknown origin. Current guidelines and recent studies consistently highlight lung adenocarcinoma as the most common primary tumor in brain metastasis cases, influencing both diagnostic patterns and management strategies.",
    "exam_year": "2021",
    "exam_type": "Part I"
  },
  {
    "question": "Case scenario of a patient with non-Hodgkin lymphoma who came with a headache? Urinary sx, has findings on brain & spine imaging, route of spreading?",
    "option_a": "Artery",
    "option_b": "Vein",
    "option_c": "Direct invasion??",
    "option_d": "Broken BBB",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuro-oncology",
    "explanation": "Understanding the route of spread is important in recognizing how systemic malignancies involve the central nervous system. In most metastatic conditions, including non-Hodgkin lymphoma, cells typically travel via the bloodstream. Non-Hodgkin lymphoma cells can enter the systemic circulation and spread hematogenously. The arterial system is primarily responsible for delivering these cells to the brain and spine, where they can then breach the blood-brain barrier. Patients presenting with headache and additional symptoms such as urinary disturbances might have multifocal involvement of both the brain and spinal cord. In non-Hodgkin lymphoma, secondary CNS involvement is often due to hematogenous spread, explaining the multifocal imaging findings. Diagnosis relies on neuroimaging (contrast-enhanced MRI of the brain and spine) and may require cerebrospinal fluid analysis. Differential diagnoses include leptomeningeal carcinomatosis from other malignancies, infectious meningitis, and other primary CNS lymphomas. Management typically involves systemic chemotherapy with high-dose methotrexate-based regimens which penetrate the CNS. In cases of leptomeningeal disease, intrathecal chemotherapy might be added. For patients who are pregnant or lactating, methotrexate is contraindicated, and alternative regimens or delayed treatment may be considered with close multidisciplinary management. Option A (Artery) is the correct answer as the arterial (hematogenous) route is most commonly implicated in disseminating lymphoma cells to both the brain and spinal cord. Option B (Vein) is less typical because the venous system generally leads to pulmonary filtration before reaching the brain. Option C (Direct invasion) is not the usual mechanism for lymphoma spread. Option D (Broken BBB) is a permissive condition rather than a route of metastasis. 1. In systemic non-Hodgkin lymphoma, CNS involvement is most commonly via hematogenous arterial spread. 2. Multifocal CNS lesions in lymphoma should prompt evaluation for both parenchymal and leptomeningeal disease. Recent studies have focused on the molecular mechanisms of lymphoma cell transmigration across the blood-brain barrier, reinforcing the role of the arterial route. Guidelines now emphasize early CNS prophylaxis in high-risk systemic lymphoma cases.",
    "exam_year": "2021",
    "exam_type": "Part I"
  },
  {
    "question": "(A pathology report: Atypia and necrosis) \u2026\u2026",
    "option_a": "GBM",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuro-oncology",
    "explanation": "Glioblastoma multiforme (GBM) is a highly aggressive primary brain tumor. It is characterized by rapid growth, extensive invasion, and histologic features such as cellular atypia and necrosis. GBM arises from glial cells and exhibits marked cellular pleomorphism, brisk mitotic activity, and areas of necrosis with pseudopalisading, which are hallmarks of its aggressive nature. Genetic alterations common in GBM include EGFR amplification and PTEN mutations. Patients with GBM typically present with rapidly progressive neurological deficits, headaches, and seizures. The presence of atypia and necrosis in a pathology report strongly supports the diagnosis of GBM, especially in adults. The diagnostic workup includes MRI with contrast, which typically shows irregular, ring-enhancing lesions. A definitive diagnosis requires histopathological examination after a biopsy or surgical resection. Differential diagnoses include anaplastic astrocytoma, metastasis, and primary CNS lymphoma. The current standard of care for GBM, as outlined by the Stupp protocol, is maximal safe surgical resection followed by radiotherapy with concurrent and adjuvant temozolomide chemotherapy. In pregnant patients, careful timing of surgery and radiotherapy is required, with multidisciplinary coordination to balance maternal benefit and fetal risk. Lactating patients require counseling regarding drug excretion in breast milk and potential infant exposure. Option A (GBM) is correct because the pathological findings of cellular atypia and necrosis are characteristic of glioblastoma multiforme. The other options are either not provided or do not correspond with these classical histopathologic features. 1. GBM is the most common primary malignant brain tumor in adults, often presenting with rapid clinical deterioration. 2. The presence of necrosis and pseudopalisading is pathognomonic for GBM. Recent trials continue to validate the Stupp regimen as the standard treatment for GBM while investigating novel targeted therapies and immunotherapeutic strategies. Ongoing research is also focused on overcoming the blood-brain barrier to improve drug delivery in these patients.",
    "exam_year": "2021",
    "exam_type": "Part I"
  },
  {
    "question": "Which brain tumor characterized by histopathological pseudorosettes?",
    "option_a": "Ependymoma",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuro-oncology",
    "explanation": "Ependymomas are glial tumors that arise from ependymal cells lining the ventricular system and central canal of the spinal cord. A hallmark of these tumors under the microscope is the formation of perivascular pseudorosettes, where tumor cells are radially arranged around blood vessels. Ependymomas develop from ependymal cells. Their characteristic arrangement in pseudorosettes occurs as the neoplastic cells cluster around central blood vessels with an intervening clear zone. This is in contrast to true rosettes found in other tumors. The process reflects the tumor\u2019s growth pattern and its interaction with the surrounding vasculature. Depending on their location, ependymomas may cause symptoms by obstructing cerebrospinal fluid pathways (resulting in hydrocephalus) or by exerting local mass effect. In children, supratentorial or posterior fossa locations are common, while in adults spinal cord ependymomas are more frequently encountered. The diagnosis is made via MRI imaging, which may reveal an intraventricular or intramedullary mass, followed by histopathological analysis confirming the presence of perivascular pseudorosettes. Differential diagnoses include medulloblastomas (which have Homer Wright rosettes) and astrocytomas, but the pseudorosette pattern is classic for ependymomas. The mainstay of treatment is maximal safe surgical resection. Adjuvant radiation therapy is considered for incomplete resections or higher grade lesions. In scenarios involving pregnancy, a multidisciplinary approach is critical; surgery is usually deferred until the second trimester if possible, and radiotherapy may be postponed postpartum when the fetus is at risk. Option A (Ependymoma) is correct because the defining histopathological feature of pseudorosettes is most typically seen in ependymomas. The absence of other options further supports this choice without introducing conflicting alternatives. 1. Pseudorosette formation is a key histological clue to diagnosing ependymoma. 2. Location of the tumor dictates clinical symptoms\u2014obstructive hydrocephalus in intracranial lesions or focal neurologic deficits in spinal lesions. 3. Surgical resection is the cornerstone of management. Recent studies emphasize complete surgical resection when possible, with adjuvant radiotherapy tailored to residual disease and tumor grade. Ongoing research into the molecular markers of ependymomas is refining prognostic assessments and treatment strategies.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Case scenario of middle aged patient presented with sudden severe headache and double vision. Her examination shows complete right ptosis and decreased visual acuity bilaterally. Right pupil 6 mm and left one 3 mm, both reacts to light. No other details and no labs. What is the possible diagnosis?",
    "option_a": "Pituitary apoplexy",
    "option_b": "Cavernous sinus fistula",
    "option_c": "Craniopharyngioma with ruptured cyst",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuro-oncology",
    "explanation": "Pituitary apoplexy is an acute, life\u2010threatening condition resulting from hemorrhage or infarction within a pituitary adenoma. It is characterized by a sudden onset of headache, visual disturbances, and cranial nerve deficits. The rapid hemorrhage or infarction within the pituitary adenoma leads to an abrupt increase in intrasellar pressure. This expansion causes compression of nearby structures such as the optic chiasm and cranial nerves (notably III, IV, and VI) in the cavernous sinus, which can result in ocular motor deficits and visual impairment. Patients typically present with a sudden, severe headache, visual disturbances (including diplopia and decreased visual acuity), and ophthalmoplegia\u2014such as ptosis from cranial nerve III involvement. In this scenario, the presence of complete right ptosis with anisocoria (right pupil larger than left) fits the profile of cranial nerve compression from pituitary apoplexy. Diagnosis is usually confirmed via neuroimaging with MRI, which reveals hemorrhage within or around the pituitary gland. Differential diagnoses include subarachnoid hemorrhage, cavernous sinus fistula (which would more likely present with pulsatile exophthalmos or a bruit), and ruptured aneurysms. Immediate management includes hemodynamic stabilization and administration of corticosteroids to address possible adrenal insufficiency. Early neurosurgical decompression is indicated in cases with significant or progressive neuro-ophthalmological deficits. In pregnant patients, the risks of surgery must be weighed against potential fetal complications, often requiring multidisciplinary planning and timing of intervention during safer gestational periods. Option A (Pituitary apoplexy) is correct because the clinical presentation of a sudden severe headache, ocular nerve deficits (ptosis with anisocoria), and visual impairment strongly points to this diagnosis. Option B (Cavernous sinus fistula) is less likely due to the absence of signs like pulsatile exophthalmos, while Option C (Craniopharyngioma with ruptured cyst) typically causes a more indolent presentation or chemical meningitis rather than the acute cranial nerve deficits seen here. 1. Sudden onset headache with ophthalmoplegia in a patient with a pituitary adenoma is highly suggestive of apoplexy. 2. Prompt administration of steroids is essential to prevent adrenal crisis. 3. Early imaging is key to diagnosis. Recent guidelines support early surgical intervention in patients with deteriorating neurologic function, while mild cases may be managed conservatively with close monitoring. Advances in neuroimaging have improved early detection, and studies continue to refine the timing of surgical decompression.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "4 years old boy diagnosed with intramedullary spinal cord tumor, non enhancing on MRI. No other details. What is the most likely diagnosis?",
    "option_a": "Meningioma",
    "option_b": "Astrocytoma",
    "option_c": "Schwannoma",
    "option_d": "Metastasis",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuro-oncology",
    "explanation": "Intramedullary spinal cord tumors are lesions found within the substance of the spinal cord. In children, the most common intramedullary tumor is an astrocytoma, which arises from the supportive glial cells within the cord. Spinal cord astrocytomas originate from astrocytes and tend to be low-grade, especially in pediatric populations. Their typically indolent growth pattern and lower vascularity often result in minimal or no enhancement on MRI scans, distinguishing them from more vascular tumors. Children with spinal cord astrocytomas usually present with a slowly progressive course of symptoms, including motor and sensory deficits, back pain, and occasionally, spinal deformities. The nonenhancing nature on MRI in a 4-year-old supports a low-grade astrocytoma rather than a more aggressive neoplasm. MRI is the gold standard for detecting intramedullary tumors. Differential diagnoses include ependymoma (which tends to enhance and is more common in older patients), as well as extramedullary lesions like meningiomas and schwannomas that typically enhance vividly and are not found within the cord parenchyma. The primary treatment for spinal cord astrocytoma is surgical resection while trying to preserve neurological function. In cases where complete resection is not possible, adjuvant radiotherapy may be considered, though its use in young children is limited because of potential long-term adverse effects. For pregnant patients, the management plan should be adapted through close collaboration among neurosurgeons, neurologists, and obstetricians to minimize risks to both the mother and fetus. Option B (Astrocytoma) is correct because the patient\u2019s age and the MRI findings of a nonenhancing intramedullary lesion strongly support this diagnosis. Option A (Meningioma) and Option C (Schwannoma) are usually extramedullary and occur in older populations; Option D (Metastasis) is exceedingly rare in a 4-year-old. 1. In pediatric intramedullary spinal cord tumors, nonenhancing lesions on MRI are more likely to be astrocytomas. 2. Ependymomas, which are the most common intramedullary tumors in adults, typically exhibit enhancement and a different location. 3. Preservation of neurological function is a key consideration during surgical resection. Current research supports the role of early surgical intervention in pediatric spinal cord astrocytomas to prevent irreversible neurological damage, with molecular studies increasingly guiding prognosis and tailored adjuvant therapy when indicated.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "57 years old male with renal cell carcinoma brought to the ED with confusion and seizure. Brain MRI shows single mass with vasogenic edema. What is the best treatment?",
    "option_a": "Chemotherapy",
    "option_b": "Radiotherapy",
    "option_c": "Surgical removal",
    "option_d": "Ablation",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Neuro-oncology",
    "explanation": "Brain metastases occur when malignant cells from a primary tumor, such as renal cell carcinoma (RCC), disseminate to the brain. These lesions can create focal neurological deficits and are often associated with surrounding edema. RCC metastasizes hematogenously, and once the tumor cells lodge in the cerebral vasculature, they disrupt the blood\u2013brain barrier, leading to vasogenic edema and a mass effect. RCC is known for its resistance to standard chemotherapy and radiotherapy, making local control via surgery critical when feasible. The patient\u2019s presentation with confusion and seizure is consistent with a space-occupying lesion in the brain. The presence of a solitary mass with vasogenic edema on MRI further corroborates the diagnosis of a metastatic lesion, likely causing localized neural irritation and increased intracranial pressure. Diagnosis is based on MRI imaging, which typically reveals the solitary lesion and its surrounding edema. Differential diagnoses include primary brain tumors (such as high-grade gliomas), brain abscesses, or other metastatic lesions. A known history of RCC makes a metastasis the most likely diagnosis. For a solitary, accessible brain metastasis, surgical removal is considered the first-line treatment, particularly when the lesion is symptomatic or causing significant mass effect. This is typically followed by adjuvant stereotactic radiosurgery (SRS) or, in some cases, whole-brain radiotherapy (WBRT) to minimize recurrence. In patients where surgery poses high risks or in the presence of multiple lesions, radiosurgery is an alternative. In pregnant or lactating patients, any surgical or radiotherapeutic intervention requires a multidisciplinary team approach to balance maternal and fetal/neonatal safety. Option C (Surgical removal) is correct because resection of a solitary metastasis, especially from RCC which is known to be less responsive to chemo- and radiotherapy, offers the best chance for symptom control and prolongation of survival. Option A (Chemotherapy) is generally ineffective for brain metastases due to the blood\u2013brain barrier, Option B (Radiotherapy) alone may not adequately control a large symptomatic mass, and Option D (Ablation) is not a standard modality for treating brain metastases. 1. Solitary brain metastases from RCC are best managed by surgical resection if accessible. 2. Vasogenic edema from metastases is often responsible for acute neurological symptoms like seizures. 3. A multimodal approach, including adjuvant radiosurgery, enhances local tumor control. Recent guidelines advocate for surgical resection followed by radiosurgery for solitary brain metastases in selected patients, reflecting improved outcomes with combined modalities. Ongoing research is exploring targeted therapies and immunotherapies for RCC which may further influence future treatment paradigms.",
    "exam_year": "2022",
    "exam_type": "Part I",
    "image_url": "page_11.png"
  },
  {
    "question": "Patient on intrathecal methotrexate presented with clinical and radiological picture that is typical for subacute combined degeneration of the cord. No labs given. Beside stopping MTX what else would you give the patient?",
    "option_a": "Vitamin E",
    "option_b": "Zink",
    "option_c": "Folate",
    "option_d": "Something else not related",
    "option_e": "",
    "correct_answer": "D",
    "subspecialty": "Neuro-oncology",
    "explanation": "Subacute combined degeneration (SCD) is a classical syndrome of dorsal column and lateral corticospinal tract demyelination most often seen in vitamin B12 deficiency. In a patient receiving intrathecal methotrexate (MTX), the clinical and radiological picture may mimic SCD because MTX interferes with folate metabolism, potentially affecting myelin synthesis. However, the treatment of true SCD is vitamin B12 supplementation \u2013 a therapy not listed explicitly among the provided options. Hence, the marked answer 'Something else not related' implies that the correct additional treatment is not vitamin E, zinc, or simple folate, but rather vitamin B12 replacement. MTX is a dihydrofolate reductase inhibitor that decreases folate availability, and, in its intrathecal form, has been associated with neurotoxicity. While MTX toxicity can cause white matter changes, the constellation of signs resembling SCD is due to demyelination typically seen in vitamin B12 deficiency. Vitamin B12 is essential for myelin formation and maintenance; its deficiency leads to defective methylation processes and subsequent demyelination of the dorsal columns and lateral corticospinal tracts. Patients with SCD usually present with paresthesias, gait ataxia, vibration and proprioception loss as well as spasticity. In the context of intrathecal MTX, a patient developing these symptoms would have an MRI showing T2 hyperintensities in the dorsal columns, mimicking the picture seen in B12 deficiency. Recognizing the pattern is key to initiating the appropriate supplementary treatment. Common differentials for dorsal column dysfunction include vitamin B12 deficiency, copper deficiency, nitrous oxide toxicity, and rarely folate deficiency itself. Laboratory evaluations with serum B12 levels, methylmalonic acid, and homocysteine are crucial. Neuroimaging (MRI) supports the diagnosis, and the pattern of involvement helps to rule out other etiologies. The foremost management of MTX-induced neurotoxicity is discontinuation of the drug. In true SCD, vitamin B12 supplementation (preferably parenteral cyanocobalamin or methylcobalamin) is the first-line therapy. In cancer patients receiving MTX, rescue with folinic acid (leucovorin) is often used to prevent systemic toxicity, but it does not address the demyelination seen in SCD. It is imperative to assess serum B12 levels. Pregnancy and lactation considerations: Vitamin B12 is safe during pregnancy and lactation. The use of B12 injections is standard, and folinic acid rescue is also deemed acceptable if needed. Option A (Vitamin E) \u2013 No role in treating demyelination due to B12 deficiency; Option B (Zinc) \u2013 Not indicated and unrelated; Option C (Folate) \u2013 While MTX interferes with folate metabolism, supplementation with folate is not the treatment for an SCD picture, which requires vitamin B12; Option D (Something else not related) \u2013 This is the best answer because the therapy that is needed is vitamin B12 replacement, which is not explicitly listed among the options. 1. Subacute combined degeneration is a hallmark of vitamin B12 deficiency, and its timely recognition is essential for preventing irreversible neurological deficits. 2. Intrathecal MTX may produce a clinical picture mimicking SCD, but the management centers on vitamin B12, not folate, even though MTX disrupts folate metabolism. 3. Always correlate the clinical picture with laboratory findings to ensure proper treatment. Recent research continues to support vitamin B12 supplementation as the cornerstone of treatment for SCD. Current guidelines emphasize discontinuing the offending agent (MTX in this case) and initiating parenteral vitamin B12 therapy. Although folinic acid rescue is standard in high-dose MTX therapy to prevent systemic toxicity, its role in reversing neurotoxicity is limited, reinforcing the need for vitamin B12 repletion.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Psudorossite",
    "option_a": "Epindaymoma",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuro-oncology",
    "explanation": "The term 'pseudorosette' describes a histopathological pattern where tumor cells are arranged around a central structure (often a blood vessel) with an intervening clear zone. This pattern is classically associated with ependymomas. In ependymomas, tumor cells emanate from ependymal cells that line the ventricular system. Their growth pattern often leads to the formation of perivascular pseudorosettes, where cells are radially arranged around blood vessels with an intervening zone of fibrillary processes, rather than true rosettes with a central lumen. Ependymomas frequently arise in the fourth ventricle in children or within the spinal cord in adults, and the presence of perivascular pseudorosettes in histology is a diagnostic clue. These tumors often present with signs of increased intracranial pressure or local neurological deficits depending on their location. Differential diagnosis when observing rosette formations includes medulloblastoma (which typically shows Homer Wright rosettes), neurocytoma, and other glial tumors. Immunohistochemical stains (e.g., GFAP positivity) and location (ventricular versus parenchymal) help differentiate ependymomas from other tumors. The treatment of ependymomas primarily involves surgical resection. In cases of incomplete resection or higher-grade tumors, adjuvant radiotherapy is recommended. In pediatric patients, and in pregnant or lactating women, the timing of surgery and the potential risks of radiotherapy must be carefully balanced; radiotherapy is generally deferred if possible during pregnancy. Long-term follow-up is essential to monitor for recurrence. Option A (Ependymoma) is correct because the presence of perivascular pseudorosettes is a hallmark of ependymoma. Other alternatives are not mentioned but would be less consistent with this histologic finding. 1. Pseudorosettes, particularly perivascular ones, are highly suggestive of ependymoma in neuropathology. 2. The location of the tumor (such as in the fourth ventricle or spinal cord) supports the diagnosis of ependymoma. 3. Immunohistochemical staining (GFAP positivity) further aids in confirming the diagnosis. Recent studies and neuropathological guidelines continue to underline the importance of histologic patterns in diagnosing ependymomas. Advancements in molecular profiling are also being incorporated into the classification and prognostication of these tumors.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Pt came with history of confusion and difficulty to arouse. MRI attached GbM with large diffuse vasogenic edema. What is your next step in management?",
    "option_a": "radiotherapy",
    "option_b": "steroid",
    "option_c": "Chemotherapy",
    "option_d": "Depulking",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuro-oncology",
    "explanation": "Glioblastoma Multiforme (GBM) is an aggressive primary brain tumor that often presents with significant vasogenic edema due to blood\u2013brain barrier disruption. The prompt management of the cerebral edema is key to reducing raised intracranial pressure and alleviating symptoms. GBM leads to the disruption of the blood\u2013brain barrier, resulting in leakage of plasma fluid into the interstitial space (vasogenic edema). This edema increases intracranial pressure and can lead to symptoms like confusion and decreased arousal. The inflammatory milieu and vascular permeability contribute to the rapid accumulation of fluid around the tumor. Patients with GBM often present with headache, altered mental status, focal neurological deficits, and signs of increased intracranial pressure. The MRI typically shows a ring-enhancing lesion with surrounding edema. The diffuse vasogenic edema explains the patient\u2019s confusion and lethargy. Differential diagnoses for a brain lesion with extensive edema include abscesses, metastatic lesions, demyelinating lesions (like tumefactive MS), or high-grade gliomas other than GBM. Neuroimaging with contrast-enhanced MRI along with clinical correlation and sometimes biopsy is necessary to distinguish these conditions. Immediate management of vasogenic edema involves the use of high-dose corticosteroids, such as dexamethasone, to reduce cerebral edema and intracranial pressure. This is a symptomatic management that stabilizes the patient before proceeding with definitive therapies, which include surgical resection (when feasible), radiotherapy, and chemotherapy (typically temozolomide). Pregnancy and lactation considerations: Dexamethasone is used in pregnancy when benefits outweigh the risks; if administered, the lowest effective dose should be used and fetal monitoring is advised. Option A (Radiotherapy), Option C (Chemotherapy), and Option D (Debulking) are all parts of the definitive management of GBM but are not the immediate next step in a patient with life\u2010threatening cerebral edema. Option B (Steroid) is correct because it quickly decreases edema and intracranial pressure, thereby stabilizing the patient before definitive treatment. 1. Dexamethasone is the mainstay of treatment for vasogenic edema in brain tumors. 2. Rapid reduction of intracranial pressure with steroids can significantly improve neurological status in patients with GBM. 3. Definitive treatment of GBM should follow after stabilization, and multidisciplinary planning is essential. Current neuro-oncology guidelines emphasize immediate corticosteroid administration in patients with symptomatic brain edema secondary to GBM. While prolonged steroid use is associated with side effects, short-term use is standard to manage acute symptoms. Recent studies also focus on the integration of corticosteroids with emerging targeted therapies.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Scenario lady with Cp angle mass. Pathology showed psamoma body. What is the diagnosis?",
    "option_a": "Meningioma",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuro-oncology",
    "explanation": "Cerebellopontine (CP) angle masses include a variety of lesions, with the most common being vestibular schwannomas and meningiomas. Psammoma bodies are laminated calcific deposits that are characteristically seen in meningiomas, serving as a histopathologic hallmark. Meningiomas arise from the meningothelial (arachnoid cap) cells of the dura mater. These tumors often exhibit whorled cellular arrangements and the formation of psammoma bodies due to dystrophic calcification. The presence of these calcified structures supports the diagnosis, especially in a CP angle mass. Patients with CP angle meningiomas may present with symptoms such as hearing loss, tinnitus, imbalance, or cranial nerve deficits depending on the tumor\u2019s size and location. The identification of psammoma bodies on histologic examination strongly correlates with a meningioma rather than other CP angle lesions like schwannomas, which typically lack this feature. Differential diagnoses for CP angle masses include vestibular schwannomas, epidermoid cysts, and arachnoid cysts. Radiologically, meningiomas often show a dural tail sign and calcifications on CT scan. Histology confirming psammoma bodies further differentiates meningiomas from other entities. The primary treatment for a meningioma is surgical resection, which may be curative for small, well-circumscribed lesions. Radiotherapy is considered for residual tumor post-surgery or for lesions that are not amenable to complete resection. In pregnant or lactating women, management requires a careful risk-benefit assessment; if the tumor is asymptomatic or slow growing, treatment may be deferred until after delivery, whereas symptomatic lesions may necessitate earlier intervention with surgery during the second trimester if feasible. Option A (Meningioma) is the correct choice given the presence of psammoma bodies, which are characteristic of meningiomas in a CP angle lesion. Other options (which are not listed explicitly) do not exhibit this histological feature. 1. Psammoma bodies are a diagnostic hallmark of meningiomas and help in distinguishing them from other CP angle tumors. 2. The presence of a dural tail on imaging further supports the diagnosis of meningioma. 3. Management is primarily surgical, with tailored considerations during pregnancy. Recent guidelines emphasize maximal safe resection for meningiomas with adjuvant radiotherapy in cases of residual or recurrent disease. Advances in neurosurgical techniques have improved outcomes, and multidisciplinary discussions are critical for managing lesions in complex anatomical regions such as the CP angle.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "long senario Mri attached oligodendrioglioma and pathology frieed egg What is the TTT plan??",
    "option_a": "radiotherapy",
    "option_b": "Chemotherapy",
    "option_c": "Depalking",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Neuro-oncology",
    "explanation": "Oligodendrogliomas are a type of diffuse glioma characterized by a 'fried egg' appearance on histopathology. They often arise in the frontal lobes and are associated with genetic markers like IDH mutation and 1p/19q codeletion, which correlate with a better response to therapy. The primary goal in management is to reduce tumor bulk and confirm the diagnosis by obtaining tissue. These tumors originate from oligodendrocytes, the myelin-producing cells, and show distinctive cellular morphology (round nuclei with clear cytoplasm \u2013 the 'fried egg' look) due to fixation artifacts. Their infiltrative nature and common calcifications seen on imaging are related to their growth pattern. The 1p/19q co-deletion and IDH mutations play a significant role in prognosis and guide adjuvant therapy decisions. Patients may present with seizures, headaches, or focal neurological deficits depending on the tumor's location. The slow-growing nature typical of low-grade lesions may result in a longer clinical course. Early surgical intervention can improve seizure control, relieve or prevent mass effect, and allow for accurate molecular profiling. Differential diagnoses include astrocytomas and mixed oligoastrocytomas. Imaging studies (MRI with contrast and CT demonstrating calcification) along with histopathological evaluation (noting the fried egg cells, calcifications, and assessing molecular markers such as 1p/19q status) are critical for diagnosis. The first-line treatment for an oligodendroglioma is maximal safe surgical resection (often termed debulking surgery), which reduces tumor burden and facilitates histological and molecular diagnosis. Adjuvant therapies such as radiotherapy and chemotherapy (e.g., PCV regimen or temozolomide) are considered based on tumor grade, residual disease, and molecular features. In pregnant or lactating patients, the timing of surgery should be coordinated with obstetrical care (often performing surgery in the second trimester when feasible), and radiotherapy or chemotherapy are generally deferred or modified due to fetal risks. Option A (radiotherapy) and Option B (chemotherapy) serve as important adjuncts but are not standalone first-line treatments in resectable oligodendrogliomas. Option C ('Depalking')\u2014although an unconventional term\u2014appears to be intended to mean debulking surgery, which is indeed the recommended initial treatment. Option D is blank. 1. The 'fried egg' appearance is pathognomonic for oligodendrogliomas. 2. Maximal safe resection (debulking) is the cornerstone of therapy. 3. Molecular markers such as 1p/19q codeletion are critical in determining prognosis and guiding adjuvant therapy. Recent studies and guidelines emphasize a tailored multimodality approach for oligodendrogliomas, with maximal safe resection first, followed by risk-adapted adjuvant therapy based on molecular characteristics. There is growing evidence for the utility of temozolomide in selected patients, paralleling traditional PCV regimens.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Rt brain lesion, with pathology showing fried egg appearance what's next, no mass effect on imaging",
    "option_a": "(Debulking surgery) is the most appropriate next step as it provides tissue diagnosis and reduces tumor burden. Option B (Gamma knife) is inappropriate for diffuse and infiltrative lesions like oligodendrogliomas. Option C (Radiotherapy) and Option D (Chemotherapy) might be used as adjuncts, but not as the initial sole therapy, particularly in the absence of a definitive tissue diagnosis.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Neuro-oncology",
    "explanation": "In lesions such as oligodendrogliomas, which display the typical 'fried egg' histopathology, obtaining a tissue diagnosis and reducing the tumor burden is essential. Even in the absence of significant mass effect, surgical intervention in the form of maximal safe resection (debulking surgery) is the key first step. Oligodendrogliomas are infiltrative tumors arising from oligodendrocytes. Their slow growth may mean that they do not always cause mass effect initially, but the tumor\u2019s infiltrative nature still warrants active management to minimize progression and alleviate associated symptoms such as seizures. Patients with right-sided brain lesions might experience focal neurological deficits or seizures even without overt radiological mass effect. Surgical debulking not only confirms the diagnosis but can also improve long-term seizure control and neurological function. While differential diagnoses include other low-grade gliomas and mixed gliomas, the presence of a 'fried egg' appearance on pathology strongly supports an oligodendroglioma. Imaging (MRI and CT) helps in assessing the lesion\u2019s extent and resectability. The treatment begins with maximal safe resection (debulking surgery) to reduce tumor load and achieve histological and molecular diagnosis. Adjuvant therapy may follow based on residual disease and tumor grade. In pregnant patients, careful planning is needed\u2014elective surgery is often deferred to the second trimester and adjuvant therapies are used with caution due to potential fetal risks. Option A (Debulking surgery) is the most appropriate next step as it provides tissue diagnosis and reduces tumor burden. Option B (Gamma knife) is inappropriate for diffuse and infiltrative lesions like oligodendrogliomas. Option C (Radiotherapy) and Option D (Chemotherapy) might be used as adjuncts, but not as the initial sole therapy, particularly in the absence of a definitive tissue diagnosis. 1. Even without mass effect, oligodendrogliomas are best managed surgically for diagnosis and tumor control. 2. Early surgical intervention can improve outcomes and facilitate planning for adjuvant therapy. 3. Radiosurgery is generally unsuitable for infiltrative gliomas. Current neuro-oncology guidelines strongly support maximal safe resection for accessible oligodendrogliomas. Recent research underscores that debulking surgery improves survival and functional outcomes, with adjuvant radiotherapy/chemotherapy reserved for residual or higher-grade tumors.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Pathology features of meningioma, also they mentioned psamoma body what's dx",
    "option_a": "(Meningioma) is correct because the presence of psammoma bodies and the tumor\u2019s dural origin are classic features of this diagnosis. Other options (not specified) are less likely given that psammoma bodies are not characteristic of other intracranial neoplasms in this context.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Neuro-oncology",
    "explanation": "Meningiomas are benign tumors arising from the meningothelial cells of the arachnoid layer and typically present as dural\u2010based masses. One of the hallmark histopathological findings is the presence of psammoma bodies, which are concentrically calcified structures seen in these tumors. Meningiomas grow slowly and are often well-circumscribed. The formation of psammoma bodies is due to dystrophic calcification from necrotic tumor cells and is a characteristic finding. Immunohistochemical staining often shows positivity for epithelial membrane antigen (EMA), supporting their meningothelial origin. Patients with meningiomas may be asymptomatic or present with headaches, seizures, or focal neurological deficits depending on the lesion\u2019s size and location. The dural attachment is a key radiological feature seen on imaging studies like MRI. The differential diagnosis includes schwannomas, hemangiopericytomas, and metastatic lesions; however, the presence of psammoma bodies along with a dural-based mass favors meningioma. Advanced imaging and histopathology with immunostaining (EMA positivity) further narrow down the diagnosis. For symptomatic meningiomas, the first-line management is surgical resection with an aim for complete removal. Adjuvant radiotherapy is considered in cases where there is incomplete resection or in recurrent disease. In pregnancy, management is typically conservative if the tumor is asymptomatic; intervention is planned during the second trimester if symptoms or complications arise. Option a (Meningioma) is correct because the presence of psammoma bodies and the tumor\u2019s dural origin are classic features of this diagnosis. Other options (not specified) are less likely given that psammoma bodies are not characteristic of other intracranial neoplasms in this context. 1. Meningiomas are the most common benign brain tumor, especially in middle-aged women. 2. Psammoma bodies are highly characteristic and a histopathological hallmark of meningioma. 3. Surgical resection is generally curative for benign meningiomas. Recent guidelines continue to support surgical resection as the mainstay for accessible meningiomas, with improved outcomes in complete resections. Molecular profiling is increasingly aiding in the classification and predicting the behavior of atypical and anaplastic forms.",
    "exam_year": "2022",
    "exam_type": "Part I"
  }
]